146 related articles for article (PubMed ID: 2483426)
1. Inhibition of converting enzyme in brain tissue and cerebrospinal fluid of rats following chronic oral treatment with the converting enzyme inhibitors ramipril and Hoe 288.
Gohlke P; Schölkens B; Henning R; Urbach H; Unger T
J Cardiovasc Pharmacol; 1989; 14 Suppl 4():S32-6. PubMed ID: 2483426
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of converting enzyme in the cerebrospinal fluid of rats after oral treatment with converting enzyme inhibitors.
Gohlke P; Urbach H; Schölkens B; Unger T
J Pharmacol Exp Ther; 1989 May; 249(2):609-16. PubMed ID: 2542535
[TBL] [Abstract][Full Text] [Related]
3. 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498): antihypertensive action and persistent inhibition of tissue converting enzyme activity in spontaneously hypertensive rats.
Unger T; Fleck T; Ganten D; Lang RE; Rettig F
Arzneimittelforschung; 1984; 34(10B):1426-30. PubMed ID: 6097269
[TBL] [Abstract][Full Text] [Related]
4. Persistent tissue converting enzyme inhibition following chronic treatment with Hoe498 and MK421 in spontaneously hypertensive rats.
Unger T; Ganten D; Lang RE; Schölkens BA
J Cardiovasc Pharmacol; 1985; 7(1):36-41. PubMed ID: 2580148
[TBL] [Abstract][Full Text] [Related]
5. [Antihypertensive action and inhibition of tissue conversion enzyme by ramipril, perindopril and enalapril in the spontaneously hypertensive rat (SHRSP)].
Unger T; Moursi MG; Lebrun C; Ganten D; Lang RE
Arch Mal Coeur Vaiss; 1986 Jun; 79(6):971-4. PubMed ID: 3026275
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular and antihypertensive activities of the novel non-sulfhydryl converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
Schölkens BA; Becker RH; Kaiser J
Arzneimittelforschung; 1984; 34(10B):1417-25. PubMed ID: 6097268
[TBL] [Abstract][Full Text] [Related]
7. Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, Hoe498 and MK421, in spontaneously hypertensive rats.
Unger T; Ganten D; Lang RE; Schölkens BA
J Cardiovasc Pharmacol; 1984; 6(5):872-80. PubMed ID: 6209494
[TBL] [Abstract][Full Text] [Related]
8. Antihypertensive action and inhibition of tissue converting enzyme (CE) by three prodrug CE inhibitors, enalapril, ramipril and perindopril in stroke-prone spontaneously hypertensive rats.
Moursi MG; Ganten D; Lang RE; Unger T
J Hypertens Suppl; 1986 Oct; 4(3):S495-8. PubMed ID: 3023591
[TBL] [Abstract][Full Text] [Related]
9. General pharmacology of ramipril.
Omosu M; Komine I; Becker RH; Schölkens BA
Arzneimittelforschung; 1988 Sep; 38(9):1309-17. PubMed ID: 2975947
[TBL] [Abstract][Full Text] [Related]
10. [Tissue renin-angiotensin system. Physiology and physiopathological value of their inhibition by ramipril].
Clauser E
Rev Prat; 1990 Jun; 40(18 Suppl):10-5. PubMed ID: 2143594
[TBL] [Abstract][Full Text] [Related]
11. Physical performance during sustained converting enzyme inhibition with Hoe 498 in conscious dogs.
Becker RH; Fieber P; Schulze KJ
Arch Int Pharmacodyn Ther; 1985 Dec; 278(2):303-13. PubMed ID: 3006617
[TBL] [Abstract][Full Text] [Related]
12. Tolerance and pharmacodynamics of the angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in healthy volunteers.
Witte PU; Metzger H; Eckert HG; Irmisch R
Arzneimittelforschung; 1984; 34(10B):1448-51. PubMed ID: 6097272
[TBL] [Abstract][Full Text] [Related]
13. The effect of the converting enzyme inhibitor HOE 498 on the renin angiotensin system of normal volunteers.
Bussien JP; Nussberger J; Porchet M; Waeber B; Brunner HR; Perisic M; Tansey MJ; Bomm M; Hajdu P
Naunyn Schmiedebergs Arch Pharmacol; 1985 Mar; 329(1):63-9. PubMed ID: 2987705
[TBL] [Abstract][Full Text] [Related]
14. Effect of angiotensin-converting enzyme inhibitor Hoe-498 on noradrenaline-induced vasoconstriction in isolated perfused mesentery of rats.
Xiang JZ; Schölkens BA
Zhongguo Yao Li Xue Bao; 1984 Jun; 5(2):104-5. PubMed ID: 6087609
[No Abstract] [Full Text] [Related]
15. Pharmacological properties of the new orally active angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl] -(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
Becker RH; Schölkens BA; Metzger M; Schulze KJ
Arzneimittelforschung; 1984; 34(10B):1411-6. PubMed ID: 6097267
[TBL] [Abstract][Full Text] [Related]
16. Effect of converting enzyme inhibitors on tissue converting enzyme and angiotensin II: therapeutic implications.
Unger T; Ganten D; Lang RE
Am J Cardiol; 1987 Apr; 59(10):18D-22D. PubMed ID: 3034027
[TBL] [Abstract][Full Text] [Related]
17. Effect of converting enzyme inhibitors on cardiac changes in experimental uremia.
Rambausek M; Mall G; Kollmar S; Ritz E
Kidney Int Suppl; 1988 Sep; 25():S201-3. PubMed ID: 2972864
[No Abstract] [Full Text] [Related]
18. Human intestinal brush border angiotensin-converting enzyme activity and its inhibition by antihypertensive Ramipril.
Stevens BR; Fernandez A; Kneer C; Cerda JJ; Phillips MI; Woodward ER
Gastroenterology; 1988 Apr; 94(4):942-7. PubMed ID: 2831105
[TBL] [Abstract][Full Text] [Related]
19. Antihypertensive action of the converting enzyme inhibitor perindopril (S9490-3) in spontaneously hypertensive rats: comparison with enalapril (MK421) and ramipril (Hoe498).
Unger T; Moursi M; Ganten D; Hermann K; Lang RE
J Cardiovasc Pharmacol; 1986; 8(2):276-85. PubMed ID: 2422465
[TBL] [Abstract][Full Text] [Related]
20. Influence of the new angiotensin converting enzyme inhibitor ramipril on several models of acute inflammation and the adjuvant arthritis in the rat.
Caspritz G; Alpermann HG; Schleyerbach R
Arzneimittelforschung; 1986 Nov; 36(11):1605-8. PubMed ID: 3028436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
